Topic: How To Invest

Q: Cryoport looks like an interesting healthcare play. What does TSI think about the stock? Thanks.

Article Excerpt

A: Cryoport Inc., $27.60, symbol CYRX on Nasdaq (Shares outstanding: 48.5 million; Market cap: $1.4 billion; www.cryoport.com), is a provider of temperature-controlled supply chain solutions for the biopharmaceutical, IVF and surrogacy, and animal-health markets worldwide. Its products include the company’s exclusive Cryoport Express liquid-nitrogen, dry-vapor shipment containers and other advanced technologies for the transportation of temperature-sensitive materials. The company’s operations are spread across 15 countries and 33 locations worldwide; together, they serve more than 3,000 customers working at biopharmaceutical, animal husbandry and reproductive medicine companies, universities, research institutions and government agencies. Cryoport’s brands include Cryoport Systems, CryoStork, MVE Biological Solutions, Cryopdp, and Cryogene. Over the last several years, the company has grown to become a leading global supplier for clinical trial teams and those working on the commercial launch of cell and gene therapies. It currently supports 626 global clinical trials; that’s up by 65 trials from a year ago. The current clinical trial pipeline includes 285 trials now in Phase 2..